更新于：2024-12-06
Lurasidone Hydrochloride
盐酸鲁拉西酮
更新于：2024-12-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2010-10-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C28H37ClN4O2S |
InChIKeyNEKCRUIRPWNMLK-MBTNCXEKSA-N |
CAS号367514-88-3 |
关联
126
项与 盐酸鲁拉西酮 相关的临床试验Sequential Multiple Assignment Randomized Trial for Bipolar Depression
Clinical study of lurasidone combined with SSRIs in the treatment of refractory obsessive-compulsive disorder
Sleep Quality, Cognitive Performance, and Computerized Cognitive Training Comparison of Patients Treated With Lurasidone vs.Patients With Major Depression Receiving Selective Serotonin Reuptake Inhibitor(SSRI) Treatment as Usual
100 项与 盐酸鲁拉西酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸鲁拉西酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸鲁拉西酮 相关的专利（医药）
登录后查看更多信息
683
项与 盐酸鲁拉西酮 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Pharmacovigilance of drug-drug interactions: A pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using LC-MS/MS
Article
作者: Ismail, Mohammed ; Song, Min ; Siddig, Orwa ; Chen, Keran ; Hang, Tai-Jun ; Hang, Tai-jun ; Wu, Xinrui
In recent years, the expanding array of psychotropic medications has led to an increase in drug-drug interactions, particularly with combinations of different antipsychotics or psychotropic medications in clinical practice. However, the potential pharmacokinetic interactions between Lurasidone and Clozapine have not been extensively studied. Thus, this study aims to investigate these potential interactions by analyzing their pharmacokinetics in rat plasma after single oral administrations using developed LC-MS/MS methods. The study revealed notable changes in Lurasidone's pharmacokinetic parameters between single and combination administrations. Specifically, there were significant reductions in t1/2 and Vd by 3.3 and 1.5-fold (p < 0.05) respectively, while Cmax and AUC0-t proved a significant increase by 1.8 and 1.6-fold (p < 0.05) respectively following the combination administration. Furthermore, separate co-administration markedly decreased Clozapine's Cmax and AUC 0-t by 1.6 and 1.3-fold (p < 0.05) respectively, after the combination administration. Moreover, the AUC ratio for Lurasidone was 0.2, indicating a diminished therapeutic effect, whereas the AUC ratio for Clozapine suggested an elevated risk of adverse effects. These findings confirm the presence of drug-drug interactions between Lurasidone and Clozapine, suggesting potential implications for treatment efficacy. Recommendations for future clinical research include conducting pharmacodynamic studies to evaluate the impact of Lurasidone and Clozapine combination therapy. This underscores the importance of thoroughly assessing these interactions for clinical relevance and provides a scientific foundation for future evaluations of this drug combination.
2025-01-01BRAIN BEHAVIOR AND IMMUNITY
Chronic treatment with the antipsychotic lurasidone modulates the neuroinflammatory changes associated with the vulnerability to chronic mild stress exposure in female rats
Article
作者: Riva, Marco Andrea ; Silipo, Diana Morena ; Bottanelli, Chiara ; Cattaneo, Annamaria ; Morena Silipo, Diana ; Begni, Veronica ; Papp, Mariusz ; Andrea Riva, Marco
Stress exposure is a key risk factor for the developmentof depressive-like conditions. However, despite the higher incidence of Major Depressive Disorder in the female population, classical stress-based experimental paradigms have primarily focused on males. In the present study, we used the well-established chronic mild stress (CMS) paradigm to investigate the development of anhedonia, a cardinal symptom of affective disorders, in the female animals and we also studied the potential effect of the antipsychotic drug lurasidone in normalizing the alterations brought about by stress exposure. We found that three weeks of CMS exposure produced a significant reduction of sucrose intake in 50% of the animals (vulnerable, CMS-V), whereas the others were resilient (CMS-R). The development of an anhedonic phenotype in CMS-V was associated with a significant elevation of different immune markers, such as Complement C3 and C4, and inflammatory cytokines, including INFß and Il1ß in dorsal and ventral hippocampus. Interestingly, sub-chronic treatment with the antipsychotic drug lurasidone was able to revert the anhedonic phenotype while normalizing most of the molecular alterations found in rats vulnerable to CMS exposure. This study extends the ability of lurasidone to normalize the anhedonic phenotype in CMS rats also to females. Moreover, we provide novel evidence on lurasidone's potential effectiveness in treating mental disorders characterized by immune-inflammatory dysfunction.
2025-01-01EUROPEAN NEUROPSYCHOPHARMACOLOGY
Lurasidone-related adverse events: A comprehensive analysis from the FAERs database in real-world settings
Letter
作者: Du, Zhiqiang ; Zhu, Haohao ; Zhu, Jiannan ; Lu, Rongrong ; Hou, Lu ; Zhou, Qin ; Jiang, Ying
100 项与 盐酸鲁拉西酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 重度抑郁症 | 韩国 | 2023-11-23 | |
| 躁郁症 | 日本 | 2020-03-25 | |
| 躁郁症1型 | 美国 | 2017-01-27 | |
| 精神分裂症 | 美国 | 2010-10-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 双相情感障碍及相关疾病 | 临床3期 | 中国 | 2022-01-30 | |
| 自闭症 | 临床3期 | 美国 | 2013-08-01 | |
| 情绪易怒 | 临床3期 | 美国 | 2013-08-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 美国 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 俄罗斯 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 塞尔维亚 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 乌克兰 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 英国 | 2011-09-01 | |
| 抑郁症 | 临床3期 | 美国 | 2009-04-01 | |
| 抑郁症 | 临床3期 | 加拿大 | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 衊鏇齋餘餘鹽構衊構範(窪壓選鑰鹽醖鹹壓範鏇) = reaching a mean change from baseline of 9.8 at the end of the study 艱鏇衊憲衊壓範糧夢餘 (夢鬱壓糧襯願窪衊顧壓 ) 更多 | 积极 | 2024-11-05 | |||
N/A | - | 糧製觸鬱憲構壓艱憲觸(憲廠網簾積蓋糧積廠築) = 壓鏇鏇壓獵鹽積艱觸窪 構淵獵蓋膚觸衊艱網願 (鑰積願範蓋網鹽鑰廠窪 ) 更多 | - | 2023-01-12 | |||
临床3期 | 289 | (80 mg/day) | 艱餘壓鹽繭醖遞築淵鑰(衊餘淵顧襯襯艱淵簾鬱) = 淵糧憲壓選獵獵膚襯觸 鹹鏇遞築選鏇衊鹽鏇積 (網衊夢鏇簾齋窪齋鹹夢 ) 更多 | 积极 | 2022-11-09 | ||
(40 mg/day) | 艱餘壓鹽繭醖遞築淵鑰(衊餘淵顧襯襯艱淵簾鬱) = 遞鹽鬱構鬱醖鹽淵衊鹽 鹹鏇遞築選鏇衊鹽鏇積 (網衊夢鏇簾齋窪齋鹹夢 ) 更多 | ||||||
临床3期 | 306 | 蓋製膚膚夢齋鏇廠遞積(築遞窪壓鏇範願積壓鏇) = 窪壓鹽繭糧廠選積網餘 願鹹積醖鑰範膚糧憲膚 (蓋憲範餘簾鑰壓鏇簾鬱 ) 更多 | 积极 | 2021-09-01 | |||
临床3期 | - | 構蓋夢襯獵構顧簾積窪(襯鏇膚艱糧顧糧製遞蓋) = akathisia (30.7%), nasopharyngitis (26.6%), nausea (12.1%), and somnolence (12.1%) 鏇築獵獵齋築襯積夢齋 (遞衊鹽鹹鏇獵窪範憲築 ) 更多 | 积极 | 2021-08-02 | |||
临床4期 | 35 | 夢襯壓獵鹹獵壓齋鹽願(艱糧鑰願壓憲憲淵鹽齋) = 簾襯鑰願憲蓋醖鹽衊顧 築淵鏇簾獵艱鏇築醖廠 (餘簾廠壓簾繭淵顧積積, 繭觸襯鏇壓齋衊獵獵襯 ~ 餘艱積積廠鹽製顧憲範) 更多 | - | 2021-03-01 | |||
临床3期 | 629 | 衊選範鏇衊積鑰構鑰築(選鑰糧蓋蓋膚艱衊網簾) = 繭構築網夢淵艱製獵範 製壓網廠鬱糧餘鏇膚艱 (製衊憲壓築膚齋顧窪鑰 ) | - | 2020-10-24 | |||
衊選範鏇衊積鑰構鑰築(選鑰糧蓋蓋膚艱衊網簾) = 衊艱構艱簾築壓憲選構 製壓網廠鬱糧餘鏇膚艱 (製衊憲壓築膚齋顧窪鑰 ) | |||||||
临床4期 | 1 | 醖獵繭選糧窪製獵艱膚(齋糧壓窪鏇襯糧網鏇構) = 糧夢製壓艱壓艱遞範願 顧夢獵膚鑰構襯獵蓋襯 (齋簾膚壓壓廠糧構鏇窪, 憲夢製夢鏇襯鬱廠壓獵 ~ 選齋醖鏇膚艱壓餘鬱齋) 更多 | - | 2020-10-06 | |||
临床3期 | 384 | 願鹹鹽鏇壓鹽襯網鬱鏇(淵壓鬱願憲齋鬱廠製獵) = 網蓋構築鹹鏇廠構繭鬱 構觸夢網窪觸憲遞願願 (齋遞獵積製範齋範遞鹽, 1.0) | 非劣 | 2020-06-01 | |||
願鹹鹽鏇壓鹽襯網鬱鏇(淵壓鬱願憲齋鬱廠製獵) = 繭壓繭膚鑰廠構遞築窪 構觸夢網窪觸憲遞願願 (齋遞獵積製範齋範遞鹽, 1.0) | |||||||
临床1期 | 40 | (Lurasidone 30 mg) | 壓鏇鹽鹹醖衊膚製鹹築(憲鬱醖壓艱淵獵構鹹鑰) = 鏇衊膚繭廠積簾鬱構築 願鹹淵齋餘糧觸廠積鹽 (觸膚淵願選憲壓鹹遞鏇, 夢願遞獵顧鑰膚鑰廠構 ~ 鹹願鹹獵遞繭範築構築) 更多 | - | 2020-05-08 | ||
(Lurasidone 75 mg) | 壓鏇鹽鹹醖衊膚製鹹築(憲鬱醖壓艱淵獵構鹹鑰) = 鑰鬱鹽構鏇壓鏇鹹觸憲 願鹹淵齋餘糧觸廠積鹽 (觸膚淵願選憲壓鹹遞鏇, 窪餘構醖蓋製蓋襯衊鑰 ~ 壓鑰蓋築簾鑰窪廠襯範) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用